How Bristol Myers Squibb’s Celgene Buyout Continued to Pay Off in Q4

1 min read

No one likes to miss the big party. But shareholders of Bristol Myers Squibb (NYSE: BMY) probably feel like they did in 2020. Shares of the drugmaker declined slightly last year while the overall market roared higher. After getting off to a good start initially in 2021, BMS stock again gave up most of its gain.

Bristol Myers Squibb announced its fourth-quarter and full-year 2020 results before the market opened on Thursday. Those results were good, but probably not good enough to get investors too excited. Here are the highlights from BMS’ Q4 update.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Target’s Latest Partnership Expands Traffic

Next Story

L Brands to Split Off Victoria’s Secret in August

Latest from Blog